Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline?

8Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Background: The HIV Dementia scale (HDS) has been recommended as a cross-sectional screen for HIVassociated neurocognitive disorder (HAND) but its longitudinal usefulness has not been optimally established. Method: 55 HIV+ participants underwent baseline and follow-up HDS screening after an average of 3.9 (SD=1.1) months. They had completed standard neuropsychological (NP) evaluations within the last 6-18 months to calculate a baseline HAND rate (49.1%) and gold standard cognitive change performance: 12.7% showed mild to moderate decline compared to normative standards for NP change; 80% confidence interval; 1-tailed, the rest of the sample was cognitively stable. After normalizing HDS raw-scores, standard regression-based change scores were developed to quantify HDS-based decline, which corrected for practice effect, regression towards the mean, and yielded individual predictions of neurocognitive change. Clinically significant decline was defined as a z-score outside the 80% confidence interval; 1-tailed. Baseline HIV disease and laboratory data were collected. Results: The magnitude of HDS reliability was very large r=0.76 (p<0.0001). HDS-testing found that 21.8% significantly declined. Compared to gold standard NP decline, the HDS showed 57% sensitivity and 82% specificity. Only participants (n=4) that declined moderately (median HDS-change z-score=-2 SD below mean of zero; at least 3-4 points decline in raw HDS-score) were congruently identified. Standard regression-based change scores did not operate optimally at smaller magnitudes of decline. HAND diagnosis (gold standard) at baseline (p<0.03) and more severe HAND were associated with greater chance of decline (p<0.03). No baseline HIV biomarkers were associated with decline. Conclusions: The HDS is a reliable screen to detect at least moderate neurocognitive decline in individuals with MND and HAD. Other screening instruments are needed to detect milder levels of neurocognitive decline. Alternatively, non-parametric statistical modelling is needed to improve predictions of individual cognitive change on such scales that typically have a restricted range of values. © 2013 Lu GM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. © 2013 Lu GM, et al.

Cite

CITATION STYLE

APA

Lu, G. M., Brew, B. J., Siefried, K. J., Draper, B., & Cysique, L. A. (2014). Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline? Journal of AIDS and Clinical Research, 5(1). https://doi.org/10.4172/2155-6113.1000269

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free